Colombian biotech firm

European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal signals growing confidence in Colombia's pharmaceutical sector and could expand regional vaccine manufacturing capacity, reducing reliance on imports. Details on the investors, funding amount and timelines have not yet been disclosed.